Daiichi Sankyo

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, and marketing of pharmaceutical products worldwide. It offers drugs, such as prasugrel, an antiplatelet agent; denosumab for treating osteoporosis and bone compilations; teneligliptin and pioglitazone type 2 diabetes mellitus inhibitors; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimers disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. The company also provides pharmaceutical drugs, including olmesartan and amlodipine antihypertensive agents; levofloxacin, a synthetic antibacterial agent; carvedilol for treating hypertension, angina pectoris, and chronic heart failure; pravastatin and atorvastatin antihyperlipidemic agents; iohexol to enhance visibility of diagnostic X-ray imaging; and loxoprofen, an anti-inflammatory analgesic. In addition, it offers naloxegol for opioid-induced constipation treatment; and colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus indication, as well as iron sucrose and ferric carboxymaltose injections for treating anemia. Further, it provides over the counter products, such as Lulu, combination cold remedy; Daiichi Sankyo Ichoyaku, a multi-ingredient digestive remedy; Loxonin S, an antipyretic analgesic; Patecs, an antiphlogistic analgesic for external use; and Transino for treating melisma. Additionally, the company offers ActHIB, a haemophilus influenzae type b vaccine; Rotarix, a rotavirus vaccine; Influenza HA Vaccine; and Live Attenuated Measles/Rubella Combined Vaccine. The company also manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, intermediates, and pharmaceuticals and drugs for animals. It has research collaboration agreement with Bristol-Myers Squibb. The company was founded in 1899 and is headquartered in Tokyo,...